AliveDx, a global in-vitro diagnostics innovator, today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its MosaiQ AiPlex® Vasculitis (VAS) assay, a multiplex test designed to improve the diagnosis of autoimmune vasculitides and Goodpasture’s disease.
Science Significance
The MosaiQ AiPlex VAS assay simultaneously detects three key autoantibody markers—anti-MPO, anti-PR3, and anti-GBM—using just 10 µl of patient serum. These markers are central to the 2022 ACR/EULAR Classification Criteria for ANCA-associated vasculitides and the 2021 KDIGO guidelines for glomerular diseases. By consolidating three tests into one automated, microarray-based run on the MosaiQ platform, AliveDx aims to deliver faster, more comprehensive diagnostic insights for clinicians managing complex autoimmune disorders.
Regulatory Significance
The FDA submission marks AliveDx’s next step in expanding MosaiQ’s regulatory footprint beyond Europe, where the assay received IVDR certification and CE-marking in July 2025. Pending FDA clearance, the MosaiQ AiPlex VAS assay would become available for U.S. clinical use, leveraging the previously FDA-listed MosaiQ instrument (Class II, 510(k)-exempt). A successful review would represent a major milestone in aligning AliveDx’s portfolio with global regulatory pathways.
Business Significance
Advertisement
AliveDx has launched over 90 IVD products globally in the past year, strengthening its portfolio across autoimmune, connective tissue, and celiac disease testing. Entry into the U.S. market for vasculitis testing positions the company to capture share in a high-value diagnostic segment while advancing its strategic vision of becoming a global leader in multiplexed, syndromic testing platforms. This FDA submission signals continued momentum in AliveDx’s expansion strategy and product commercialization pipeline.
Patients’ Significance
For patients, the assay offers the potential for earlier, more accurate, and less invasive testing, which may accelerate treatment decisions in life-threatening autoimmune vasculitides. By reducing turnaround time and consolidating multiple markers into one report, clinicians can achieve greater diagnostic clarity, leading to improved patient outcomes and reduced healthcare burden.
Policy Significance
The submission aligns with global policy emphasis on precision diagnostics and value-based healthcare. With autoimmune diseases contributing significantly to morbidity and healthcare costs, validated multiplex platforms such as MosaiQ support laboratory efficiency, clinical decision-making, and payer objectives. FDA clearance would represent a regulatory precedent in advancing multiplex autoimmune diagnostics under evolving U.S. diagnostic policy frameworks.
Transaction Highlights
The 510(k) submission represents a strategic milestone for AliveDx, headquartered in Eysins, Switzerland, as it seeks to expand its MosaiQ AiPlex® Vasculitis (VAS) assay into the U.S. market. The multiplex assay, designed to detect anti-MPO, anti-PR3, and anti-GBM autoantibodies, runs on the FDA-listed MosaiQ instrument (Class II, 510(k) exempt) and supports the diagnosis of ANCA-associated vasculitides and Goodpasture’s disease. Already CE-marked and IVDR-certified in Europe since July 2025, the VAS assay builds on AliveDx’s momentum, with more than 90 new IVD product launches globally in the past year. The submission underscores the company’s commitment to advancing its multiplex syndromic testing platform while creating additional value for clinicians, laboratories, and patients worldwide.
Source: AliveDx Press Release
